Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.53 |
| ▸ | ALPL | P05186 | 9/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817376 | 0.80 | RAB9A (0.53) | HCAR2ALPLCA9CA12TP53 | |
| SCHEMBL1431995 | 0.79 | ALPL (0.54) | HCAR2ALPLCA9HCAR3CA12 | |
| SCHEMBL20455653 | 0.79 | HCAR3 (0.45) | HCAR2ALPLCA9HCAR3CA12 | |
| SCHEMBL16763221 | 0.79 | HCAR3 (0.50) | HCAR2ALPLCA9HCAR3CA12 | |
| SCHEMBL24589280 | 0.77 | HCAR2 (0.37) | HCAR2ALPLTP53MAPK1 | |
| SCHEMBL26054148 | 0.77 | TP53 (0.47) | HCAR2ALPLCA9HCAR3CA12 | |
| SCHEMBL9936997 | 0.77 | HPGDS (0.50) | HCAR2ALPLHCAR3CA12TP53 | |
| SCHEMBL1092 | 0.76 | HCAR3 (0.54) | HCAR2ALPLCA9HCAR3CA12 | |
| SCHEMBL29148587 | 0.76 | HCAR3 (0.39) | HCAR2ALPLCA9HCAR3CA12 | |
| SCHEMBL6110959 | 0.76 | ALPL (0.46) | HCAR2ALPLCA9HCAR3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4291176-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117136052-A | CDK inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023274397-A1 | CDK2 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海拓界生物医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| WO-2023274397-A1 | CDK2 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海拓界生物医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| CN-102596910-A | Androgen receptor modulating compounds | ORION CORP | 2012-07-18 | — | — | CN | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1633351-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005011677-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ACE, AGTR2, ACE2 | HCAR2 52/4885ALPL 982/4885CA9 2627/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | HCAR2 364/4885ALPL 3230/4885CA9 2297/4885 |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HCAR2 364/4885ALPL 3230/4885CA9 2297/4885 |
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | HCAR2 4227/4885ALPL 2689/4885CA9 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.